Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT07397338
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors
  • CRC
  • Colorectal Cancer (CRC)
  • Metastatic Solid Tumors
  • NSCLC
  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Daraxonrasib — DRUG
    oral tablets
  • Elironrasib — DRUG
    oral tablets
  • Zoldonrasib — DRUG
    oral tablets
  • Ivonescimab — DRUG
    IV infusion
  • Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) — DRUG
    IV infusion
  • cetuximab (Cohort C2 Only) — DRUG
    IV infusion
  • Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) — DRUG
    IV infusion
  • Daraxonrasib (Cohort B1 only) — DRUG
    oral tablets

Study Details

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Key Dates

First listed
Feb 9, 2026
Start date
Jan 30, 2026
Status verified
Jul 2026
Primary completion
May 31, 2029
Completion
May 31, 2029

Study Design

Enrollment
370 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: Daraxonrasib + Ivonescimab Combination
    Dose Exploration and Dose Expansion (+ Carboplatin/Cisplatin + Pemetrexed)
  • Experimental: Arm B: Elironrasib + Ivonescimab Combination
    Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort B1 (+ daraxonrasib) and Cohort B2 (+ Carboplatin/Cisplatin + Pemetrexed).
  • Experimental: Arm C: Zoldonrasib + Ivonescimab Combination
    Dose Exploration and Dose Expansion. Dose Expansion will include two separate cohorts: Cohort C1 and Cohort C2 (+ Cetuximab).

Primary Outcome Measure

Number of patients with adverse events (AEs) [ Time Frame: Up to approximately 4 years ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033
Lorraine Martinez Seng, RN
[email protected]
323-865-0967
Eastern Connecticut Hematology and Oncology AssociatesNorwichConnecticut06360
Spiro Curis
[email protected]
860-886-8362
Health Partners Cancer Center at Regions HospitalSaint PaulMinnesota55101
Lisa Wahowske
[email protected]
651-254-1517
Tennessee OncologyNashvilleTennessee37023
Henry Black
[email protected]
615-879-6410
MD Anderson Cancer CenterHoustonTexas77030
Ly Nguyen
[email protected]
832-794-3672
MD Anderson Cancer CenterHoustonTexas77030
Ly M. Nguyen
[email protected]
832-794-3672
NEXT DallasIrvingTexas75039
Mofopefoluwa "Fope" Akinwale
[email protected]
972-893-8800
NEXT OncologySan AntonioTexas78229
Jordan Georg
[email protected]
210-580-9521
NEXT VirginiaFairfaxVirginia22031
Maybelle De La Rosa
[email protected]
703-783-4518

Find similar trials in Los Angeles, CA

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials
By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
USC Norris Comprehensive Cancer Center· Los Angeles, CAEastern Connecticut Hematology and Oncology Associates· Norwich, CTHealth Partners Cancer Center at Regions Hospital· Saint Paul, MNTennessee Oncology· Nashville, TNMD Anderson Cancer Center· Houston, TXNEXT Dallas· Irving, TX

Related Studies